GURUFOCUS.COM » STOCK LIST » USA » NAS » HilleVax Inc (NAS:HLVX) » Definitions » Cash-to-Debt
Switch to:

HilleVax Cash-to-Debt

: 0.79 (As of Dec. 2021)
View and export this data going back to 2022. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. HilleVax's cash to debt ratio for the quarter that ended in Dec. 2021 was 0.79.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, HilleVax couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2021.

The historical rank and industry rank for HilleVax's Cash-to-Debt or its related term are showing as below:

HLVX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15   Med: 0.47   Max: 0.79
Current: 0.79

During the past 2 years, HilleVax's highest Cash to Debt Ratio was 0.79. The lowest was 0.15. And the median was 0.47.

HLVX's Cash-to-Debt is ranked worse than
86.59% of 1558 companies
in the Biotechnology industry
Industry Median: 11.43 vs HLVX: 0.79

HilleVax Cash-to-Debt Historical Data

The historical data trend for HilleVax's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HilleVax Annual Data
Trend Dec20 Dec21
Cash-to-Debt
0.15 0.79

HilleVax Semi-Annual Data
Dec20 Dec21
Cash-to-Debt 0.15 0.79

Competitive Comparison

For the Biotechnology subindustry, HilleVax's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

HilleVax Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, HilleVax's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where HilleVax's Cash-to-Debt falls into.



HilleVax Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

HilleVax's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

HilleVax's Cash to Debt Ratio for the quarter that ended in Dec. 2021 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HilleVax  (NAS:HLVX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


HilleVax Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of HilleVax's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


HilleVax Business Description

HilleVax logo
Traded in Other Exchanges
N/A
Address
Website
Executives
Fhmls X, L.l.c. 10 percent owner 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101
Dubin Gary director C/O HILLEVAX, INC. 75 STATE STREET, SUITE 100 - #9995 BOSTON MA 02109
Borkowski Astrid officer: Chief Medical Officer C/O HILLEVAX, INC. 75 STATE STREET, SUITE 100 - #9995 BOSTON MA 02109
Sepulveda Jaime director C/O HILLEVAX INC. 75 STATE STREET 100 - #9995 BOSTON MA 02109
Takeda Vaccines, Inc. 10 percent owner 75 SIDNEY STREET CAMBRIDGE MA 02139
Chu Shelley director ONE WINTHROP SQUARE SUITE 400 BOSTON MA 02110
Silbermann Susan Michele director C/O LIANBIO 103 CARNEGIE CENTER DRIVE, SUITE 215 PRINCETON NJ 08540
Fhmls X, L.p. 10 percent owner 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101
Frazier Life Sciences X, L.p. 10 percent owner 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101
Gerberding Julie L. director 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033
Kohli Aditya director, officer: Chief Operating Officer C/O PHATHOM PHARMACEUTICALS, INC. 2150 E. LAKE COOK ROAD, SUITE 800 BUFFALO GROVE IL 60089
Socks David A officer: CFO & Chief Business Officer C/O CADENCE PHARMACEUTICALS, INC. 12481 HIGH BLUFF DRIVE, SUITE 200 SAN DIEGO CA 92130
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU TOKYO M0 103-8668
Hershberg Robert director, officer: President and CEO 3005 FIRST AVENUE SEATTLE WA 98121
Topper James N 10 percent owner 550 HAMILTON AVENUE, SUITE 100 PALO ALTO CA 94301
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)